0001493152-24-025433.txt : 20240627 0001493152-24-025433.hdr.sgml : 20240627 20240627161016 ACCESSION NUMBER: 0001493152-24-025433 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20240621 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240627 DATE AS OF CHANGE: 20240627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Beyond Air, Inc. CENTRAL INDEX KEY: 0001641631 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 473812456 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38892 FILM NUMBER: 241079254 BUSINESS ADDRESS: STREET 1: 900 STEWART AVENUE STREET 2: SUITE 301 CITY: GARDEN CITY STATE: NY ZIP: 11530 BUSINESS PHONE: 516-665-8200 MAIL ADDRESS: STREET 1: 900 STEWART AVENUE STREET 2: SUITE 301 CITY: GARDEN CITY STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: AIT Therapeutics, Inc. DATE OF NAME CHANGE: 20170117 FORMER COMPANY: FORMER CONFORMED NAME: KokiCare, Inc. DATE OF NAME CHANGE: 20150507 8-K 1 form8-k.htm
false 0001641631 0001641631 2024-06-21 2024-06-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 21, 2024

 

 

 

Beyond Air, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38892   47-3812456

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

900 Stewart Avenue, Suite 301

Garden City, NY 11530

(Address of Principal Executive Offices and Zip Code)

 

(516) 665-8200

Registrant’s Telephone Number, Including Area Code

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $.0001 per share   XAIR   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

First Amendment to Loan Documents

 

On June 21, 2024 (the “Amendment Closing Date”), Beyond Air, Inc. (the “Company”) and its wholly owned subsidiary, Beyond Air Ltd. (the “Guarantor”), entered into that certain First Amendment to Loan Documents (the “First Amendment”), with Avenue Capital Management II, L.P., as administrative agent and collateral agent (the “Agent”), Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership (“Avenue”), and Avenue Venture Opportunities Fund II, L.P, a Delaware limited partnership (“Avenue 2” and, together with Avenue, the “Lenders”), which amends (i) that certain Loan and Security Agreement (the “Agreement”), dated as of June 15, 2023 (the “Initial Closing Date”), among the Company, as borrower, the Guarantor, the Agent and the Lenders and (ii) that certain Supplement to the Agreement (collectively with the Agreement, the “Loan Agreement”), dated as of the Initial Closing Date, among the Company, the Guarantor, the Agent and the Lenders.

 

As previously disclosed, the Loan Agreement provides for senior secured term loans (the “Loans”) in an aggregate principal amount up to $40.0 million, with (i) $17.5 million advanced on the Initial Closing Date (“Tranche 1”), (ii) up to $10.0 million which may be advanced upon the request of the Company between April 1, 2024 and September 30, 2024, subject to the Company having achieved total revenue derived from the sale of LungFit PH (other than licensing revenue) (“Product Revenue”) for the three-month period prior to funding of not less than 85% of projected Product Revenue for such period (“Tranche 2”), and (iii) up to $12.5 million which may be advanced after April 1, 2024 (the “Discretionary Tranche”), subject to (a) the Agent and Lenders having received investment committee approval and (b) the Company and Lenders having mutually agreed to draw and fund, respectively, such amount. The Loans are due and payable on June 1, 2027 (the “Maturity Date”). The Loans bear interest at a rate per annum (subject to increase during an event of default) equal to the greater of (i) the prime rate, as published by the Wall Street Journal from time to time, plus 3.75% and (ii) 12.00%.

 

Following the expiration of an initial interest-only period, the Loan principal is repayable in equal monthly installments. Pursuant to the First Amendment, the expiration date of the interest-only period was extended from December 15, 2024 (with amortization payments commencing on January 1, 2025) to June 30, 2025 (with amortization payment commencing on July 1, 2025), with the possibility of further deferring principal payments an additional 12 months contingent upon the Company’s achievement of at least $40.0 million of product revenue in the fiscal year ending March 31, 2025 and whether the Company has fully drawn Tranche 2.

 

In connection with the First Amendment, the Company paid an amendment fee of $87,500, with an additional $87,500 final payment fee to be due upon the Maturity Date or any earlier date of prepayment in full of the Loans.

 

The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by reference to the text of the First Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Warrants

 

On the Amendment Closing Date, the Company issued to each of Avenue and Avenue 2 (collectively, the “Warrantholders”) warrants to purchase up to 40,000 and 60,000 shares, respectively, of Company common stock (each, a “Warrant” and collectively, the “Warrants”). The Warrants expire on June 30, 2029 (the “Expiration Date”) and have an exercise price per share of $1.28.

 

The Warrantholders may exercise the Warrants at any time, or from time to time up to and including the Expiration Date, by making a cash payment equal to the exercise price multiplied by the quantity of shares. The Warrantholders may also exercise the Warrants on a cashless basis by receiving a net number of shares calculated pursuant to the formula set forth in the Warrants. The Warrants are subject to anti-dilution adjustments for stock dividends, stock splits, and reverse stock splits.

 

The Company intends to file, within 60 days of the Amendment Closing Date, with the U.S. Securities and Exchange Commission a registration statement registering the resale of all of the shares of Company common stock issuable upon exercise of the Warrants.

 

The foregoing description of the Warrants does not purport to be complete and is qualified in its entirety by reference to the text of the Warrants, which are filed as Exhibit 4.1 and Exhibit 4.2 to this Current Report on Form 8-K and are incorporated herein by reference.

 

 
 

 

Item 2.02. Results of Operations and Financial Condition.

 

On June 24, 2024, the Company issued a press release announcing financial results for its fourth fiscal quarter and year ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

 

This information, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03 of this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

No.

  Description
4.1   Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund, L.P., dated as of June 21, 2024.
4.2   Warrant to Purchase Common Stock, by and between Beyond Air, Inc. and Avenue Venture Opportunities Fund II, L.P., dated as of June 21, 2024.
10.1   First Amendment to Loan Documents, by and among Beyond Air, Inc., Beyond Air Ltd., Avenue Capital Management II, L.P., as Agent, and the Lenders party thereto, dated as of June 21, 2024.
99.1   Press Release from Beyond Air, Inc., dated as of June 24, 2024.
104   Cover Page Interactive Data File (embedded within the inline XBRL document).

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BEYOND AIR, Inc.
     
Date: June 27, 2024 By: /s/ Steven A. Lisi
  Name: Steven A. Lisi
  Title Chief Executive Officer

 

 

EX-4.1 2 ex4-1.htm

 

Exhibit 4.1

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

Date of Issuance: June 21, 2024

 

WARRANT TO PURCHASE

 

SHARES OF COMMON STOCK OF

 

BEYOND AIR, INC.

 

(Void after June 30, 2029)

 

This certifies that AVENUE VENTURE OPPORTUNITIES FUND, LP, a Delaware limited partnership, or permitted assigns (“Holder”), for value received, is entitled to purchase from BEYOND AIR, INC., a Delaware corporation (“Company”), the Applicable Number (hereinafter defined) of fully paid and nonassessable shares of the Company’s Common Stock (the “Common Stock”), for cash, at a purchase price per share equal to the Exercise Price (hereinafter defined). Holder may also exercise this Warrant on a cashless or “net issuance” basis as described in Section 1(b) below, and this Warrant shall be deemed to have been exercised in full on such basis on the Expiration Date (hereinafter defined), to the extent not fully exercised prior to such date. This Warrant is issued in connection with that certain Loan and Security Agreement and Supplement thereto, both of even date herewith (as amended, restated and supplemented from time to time, the “Loan Agreement” and the “Supplement”, respectively), between Company, as borrower, and Holder, as one of the lenders (“Lender”). Capitalized terms used herein and not otherwise defined in this Warrant shall have the meaning(s) ascribed to them in the Loan Agreement and the Supplement, unless the context would otherwise require.

 

In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated below:

 

Applicable Number” means 40,000.

 

Exercise Price” means $1.28.

 

Warrant Shares” means the shares of Common Stock purchased hereunder.

 

Subject to Section 4.3, this Warrant may be exercised at any time or from time to time up to and including 5:00 p.m. (Pacific time) on June 30, 2029 (the “Expiration Date”), upon surrender to Company at its principal office at 900 Stewart Avenue, Suite 301, Garden City, NY 11530 (or at such other location as Company may advise Holder in writing) of this Warrant properly endorsed with the Form of Subscription attached hereto duly completed and signed and upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is being exercised determined in accordance with the provisions hereof. The Exercise Price and the number of shares purchasable hereunder are subject to further adjustment as provided in Section 4 of this Warrant.

 

 
 

 

This Warrant is subject to the following terms and conditions:

 

1. Exercise; Issuance of Certificates; Payment for Shares.

 

(a) Unless an election is made pursuant to clause (b) of this Section 1, this Warrant shall be exercisable at the option of Holder, at any time or from time to time, on or before the Expiration Date for all or any portion of the Warrant Shares (but not for a fraction of a share) for the Exercise Price multiplied by the number of Warrant Shares to be purchased. Company agrees that the Warrant Shares purchased under this Warrant shall be and are deemed to be issued to Holder as the record owner of such Warrant Shares as of the close of business on the date on which the form of subscription shall have been delivered and payment made for such Warrant Shares. Subject to the provisions of Section 2, certificates for the Warrant Shares so purchased, together with any other securities or property to which Holder is entitled upon such exercise, shall be delivered to Holder by Company at Company’s expense within a reasonable time after the rights represented by this Warrant have been so exercised. Except as provided in clause (b) of this Section 1, in case of a purchase of less than all the Warrant Shares, Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the balance of the Warrant Shares surrendered upon such purchase to Holder within a reasonable time. Each stock certificate or book-entry statement so delivered shall be in such denominations of Common Stock as may be requested by Holder and shall be registered in the name of such Holder or such other name as shall be designated by such Holder, subject to the limitations contained in Section 2.

 

(b) Holder, in lieu of exercising this Warrant by the cash payment of the Exercise Price pursuant to clause (a) of this Section 1, may elect, at any time on or before the Expiration Date, to surrender this Warrant and receive that number of Warrant Shares computed using the following formula:

 

 

 

  Where: X = the number of shares of Common Stock to be issued to Holder.
         
    Y = the number of shares of Common Stock that Holder would otherwise have been entitled to purchase hereunder pursuant to Section 1(a) (or such lesser number of shares as Holder may designate in the case of a partial exercise of this Warrant).
         
    A = the closing price on the last trading day prior to the exercise of the Warrant.
         
    B = the Exercise Price then in effect.

 

Election to exercise under this Section 1(b) may be made by delivering a signed form of subscription to Company via electronic mail, to be followed by delivery of this Warrant. Notwithstanding anything to the contrary contained in this Warrant, if as of the close of business on the last business day preceding the Expiration Date this Warrant remains unexercised as to all or a portion of the Warrant Shares, then effective at 9:00 a.m. (Pacific time) on the Expiration Date, Holder shall be deemed, automatically and without need for notice to Company, to have elected to exercise this Warrant in full pursuant to the provisions of this Section 1(b), and upon surrender of this Warrant shall be entitled to receive that number of Warrant Shares computed using the above formula, provided that the application of such formula as of the Expiration Date yields a positive number for “X”.

 

 
 

 

2. Limitation on Transfer.

 

(a) This Warrant and the Warrant Shares shall not be transferable except upon the conditions specified in this Section 2, which conditions are intended to ensure compliance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”). Each holder of this Warrant or the Warrant Shares issuable hereunder will cause any proposed transferee of the Warrant or Warrant Shares to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Section 2. Notwithstanding the foregoing and any other provision of this Section 2 but subject to the last sentence of Section 2(c), Holder may freely transfer all or part of this Warrant or the shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the shares, if any) at any time to any affiliate of Lender under the Loan Agreement, by giving Company notice of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to Company for reissuance to the transferees(s) (and Holder, if applicable).

 

(b) Each certificate representing (i) this Warrant, (ii) the Warrant Shares, and (iii) any other securities issued in respect of the Warrant Shares issued upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of this Section 2 or unless such securities have been registered under the Securities Act or sold under Rule 144) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable state securities laws):

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

(c) Holder of this Warrant and each person to whom this Warrant is subsequently transferred represents and warrants to Company and agrees (by acceptance of such transfer) that it will not transfer this Warrant (or securities issuable upon exercise hereof unless a registration statement under the Securities Act was in effect with respect to such securities at the time of issuance thereof) unless (i) there is an effective registration statement under the Securities Act and applicable state securities laws covering any such transaction, (ii) pursuant to Rule 144 under the Securities Act (or any other rule under the Securities Act relating to the disposition of securities), (iii) Company receives an opinion of counsel, reasonably satisfactory to Company, that an exemption from such registration is available or (iv) the Company otherwise satisfies itself that such transaction is exempt from registration. Notwithstanding the foregoing or any other provision of this Section 2, Holder shall not transfer this Warrant (or securities issuable upon exercise hereof, or securities issuable, directly or indirectly, upon conversion of such securities, if any) to any competitor of Company, as determined in good faith by the Board of Directors of Company (the “Board”), without the prior written consent of Company.

 

(d) Reserved.

 

 
 

 

3. Shares to be Fully Paid; Reservation of Shares. Company covenants and agrees that all Warrant Shares will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any stockholder and free of all taxes, liens and charges with respect to the issue thereof. Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, Company will at all times have authorized and reserved, for the purpose of exercise of the this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant. Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon which the Common Stock may be listed. Company will not take any action which would result in any adjustment of the Exercise Price (as described in Section 4 hereof) (i) if the total number of Warrant Shares issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon exercise of all options and upon the conversion of all convertible securities then outstanding, would exceed the total number of shares of Common Stock then authorized by Company’s Certificate of Incorporation, as amended and restated from time to time (the “Charter”) or (ii) if the par value per share of the Common Stock would exceed the Exercise Price.

 

4. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 4. Upon each adjustment of the Exercise Price, Holder of this Warrant shall thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of Warrant Shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product thereof by the Exercise Price resulting from such adjustment.

 

4.1 Subdivision or Combination of Stock. In case Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of Common Stock of Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased.

 

4.2 Dividends. If at any time or from time to time the holders of Common Stock (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,

 

(a) Common Stock, or any shares of stock or other securities whether or not such securities are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,

 

(b) any cash paid or payable including as a cash dividend, or

 

(c) Common Stock or other or additional stock or other securities or property (including cash) by way of spin off, split-up, reclassification, combination of shares or similar corporate rearrangement, (other than shares of Common Stock issued as a stock split, adjustments in respect of which shall be covered by the terms of Section 4.1 above),

 

then and in each such case, Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clauses (b) and (c) above) which such Holder would hold on the date of such exercise had it been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares and/or all other additional stock and other securities and property.

 

 
 

 

4.3 Change of Control. In the event of a Change of Control (as hereinafter defined), this Warrant shall be automatically exchanged for a number of shares of Company’s securities, such number of shares being equal to the maximum number of shares issuable pursuant to the terms hereof (after taking into account all adjustments described herein) had Holder elected to exercise this Warrant immediately prior to the closing of such Change of Control and purchased all such shares pursuant to the cashless exercise provision set forth in Section 1(b). Company acknowledges and agrees that Holder shall not be required to make any payment (cash or otherwise) for such shares as further consideration for their issuance pursuant to the terms of the preceding sentence. “Change of Control” shall mean any sale, license, or other disposition of all or substantially all of the assets of Company, any reorganization, consolidation, merger or other transaction involving Company where the holders of Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction; provided that an issuance of equity securities for the primary purpose of raising capital shall not be considered a Change of Control under this Warrant. This Warrant shall terminate upon Holder’s receipt of the number of shares of Company’s equity securities described in this Section 4.3.

 

4.4 Reserved.

 

4.5 Notice of Adjustment. Upon any adjustment of the Exercise Price, and/or any increase or decrease in the number of Warrant Shares purchasable upon the exercise of this Warrant, Company shall give written notice thereof to Holder pursuant to Section 12. The notice, which may be substantially in the form of Exhibit “A” attached hereto, shall be signed by Company’s chief financial officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.

 

4.6 Other Notices. If at any time:

 

(a) Company shall declare any cash dividend upon its Common Stock;

 

(b) Company shall declare any dividend upon its Common Stock payable in stock or make any special dividend or other distribution to the holders of its Common Stock;

 

(c) Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights;

 

(d) there shall be any capital reorganization or reclassification of the capital stock of Company, or consolidation or merger of Company with, or sale of all or substantially all of its assets to, another entity;

 

(e) there shall be a voluntary or involuntary dissolution, liquidation or winding-up of Company; or

 

(f) Company shall take or propose to take any other action, notice of which is actually provided to holders of the Common Stock;

 

then, in any one or more of said cases, Company shall give Holder, pursuant to Section 12, (i) at least 10 days’ prior written notice of the date on which the books of Company shall close or a record shall be taken for such dividend, distribution or subscription rights or for determining rights to vote in respect of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action and (ii) in the case of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action, at least 10 days’ written notice of the date when the same shall take place. Any notice given in accordance with the foregoing clause (i) shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common Stock shall be entitled thereto. Any notice given in accordance with the foregoing clause (ii) shall also specify the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action as the case may be.

 

 
 

 

4.7 Certain Events. If any change in the outstanding Common Stock of Company or any other event occurs as to which the other provisions of this Section 4 are not strictly applicable or if strictly applicable would not fairly effect the adjustments to this Warrant in accordance with the essential intent and principles of such provisions, then the Board shall make in good faith an adjustment in the number and class of shares issuable under this Warrant, the Exercise Price and/or the application of such provisions, in accordance with such essential intent and principles, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give Holder of this Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as Holder would have owned had this Warrant been exercised prior to the event and had Holder continued to hold such shares until after the event requiring adjustment.

 

5. Issue Tax. The issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be made without charge to Holder of this Warrant for any issue tax in respect thereof; provided, however, that Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the then Holder of this Warrant being exercised.

 

6. Closing of Books. Company will at no time close its transfer books against the transfer of this Warrant or of any Warrant Shares issued or issuable upon the exercise of this Warrant in any manner which interferes with the timely exercise of this Warrant.

 

7. No Voting Rights; Limitation of Liability. Nothing contained in this Warrant shall be construed as conferring upon Holder hereof the right to vote or to consent as a stockholder in respect of meetings of stockholders for the election of directors of Company or any other matters or any rights whatsoever as a stockholder of Company. No dividends or interest shall be payable in respect of this Warrant or the interest represented hereby or the shares purchasable hereunder until, and only to the extent that, this Warrant shall have been exercised; provided, however, that if any dividends are due or paid at any time on the underlying securities for which this Warrant is exercisable, then upon exercise, the securities issued to Holder shall be deemed to have accrued dividends and be paid identical dividends from date of this Warrant. No provisions hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a stockholder of Company, whether such liability is asserted by Company or by its creditors.

 

8. Amendment of Charter. Unless Holder consents thereto in writing, Company shall not amend its Charter prior to the exercise of this Warrant if the Common Stock would be adversely affected by such amendment in a manner that would be more adverse to Holder with respect to the shares of Common Stock issuable upon the exercise of this Warrant than, and substantially dissimilar to, such amendment’s effect on the other holders of Common Stock.

 

9. Registration Rights. Holder shall be entitled, with respect to the shares of Common Stock issued upon exercise hereof, to the registration rights set forth in Section 3(d) of the Supplement.

 

10. Rights and Obligations Survive Exercise of Warrant. The rights and obligations of Company, of Holder of this Warrant and of the holder of Warrant Shares, contained in Sections 6, 8 and 18 shall survive the exercise of this Warrant.

 

11. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.

 

12. Notices. Any notice, request or other document required or permitted to be given or delivered to Holder or Company shall be deemed to have been given (i) upon receipt if delivered personally or by courier (ii) upon confirmation of receipt if by facsimile or email or (iii) three business days after deposit in the US mail, with postage prepaid and certified or registered, to each such Holder at its address as shown on the books of Company or to Company at the address indicated therefor in the opening paragraphs of this Warrant (or at such other location as Company may advise Holder in writing).

 

 
 

 

13. Survival of Certain Obligations. All of the obligations of Company relating to the Warrant Shares issuable upon the exercise of this Warrant shall survive the exercise and termination of this Warrant. All of the covenants and agreements of Company shall inure to the benefit of and be binding upon the successors and permitted assigns of Holder. Company will, at the time of the exercise of this Warrant, in whole or in part, upon request of Holder but at Company’s expense, acknowledge in writing its continuing obligation to Holder in respect of any rights to which Holder shall continue to be entitled after such exercise in accordance with this Warrant; provided, that the failure of Holder to make any such request shall not affect the continuing obligation of Company to Holder in respect of such rights.

 

14. Descriptive Headings and Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware.

 

15. Lost Warrants or Stock Certificates. Company agrees that upon receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction, or mutilation of any Warrant or stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, Company at its expense will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 

16. Fractional Shares. No fractional shares shall be issued upon exercise of this Warrant. Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price.

 

17. Representations of Holder. With respect to this Warrant, Holder represents and warrants to Company as follows:

 

17.1 Experience. It is experienced in evaluating and investing in companies engaged in businesses similar to that of Company; it understands that investment in this Warrant involves substantial risks; it has made detailed inquiries concerning Company, its business and services, its officers and its personnel; the officers of Company have made available to Holder any and all written information it has requested; the officers of Company have answered to Holder’s satisfaction all inquiries made by it; in making this investment it has relied upon information made available to it by Company; and it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of investment in Company and it is able to bear the economic risk of that investment.

 

17.2 Investment. It is acquiring this Warrant and any Warrant Shares issuable upon exercise hereof for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. It understands that this Warrant and the Warrant Shares issuable upon exercise of this Warrant, have not been registered under the Securities Act, nor qualified under applicable state securities laws.

 

17.3 Rule 144. It acknowledges that this Warrant and the Common Stock issuable upon exercise of this Warrant must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. It has been advised or is aware of the provisions of Rule 144 promulgated under the Securities Act.

 

17.4 Access to Data. It has had an opportunity to discuss Company’s business, management and financial affairs with Company’s management and has had the opportunity to inspect Company’s facilities.

 

 
 

 

17.5 Accredited Investor. It is, and at the time the Warrant was offered was, an “accredited investor” within the meaning of Regulation D promulgated under the Securities Act.

 

17.6 General Solicitation. It is not purchasing this Warrant as a result of any advertisement, article, notice or other communication regarding this Warrant published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to its knowledge, any other general solicitation or general advertisement.

 

18. Additional Representations and Covenants of Company. Company hereby represents, warrants and agrees as follows:

 

18.1 Corporate Power. Company has all requisite corporate power and corporate authority to issue this Warrant and to carry out and perform its obligations hereunder.

 

18.2 Authorization. All corporate action on the part of Company, its directors and stockholders necessary for the authorization, execution, delivery and performance by Company of this Warrant has been taken. This Warrant is a valid and binding obligation of Company, enforceable in accordance with its terms.

 

18.3 Offering. Subject in part to the truth and accuracy of Holder’s representations set forth in Section 17 hereof, the offer, issuance and sale of this Warrant is, and the Common Stock issuable upon exercise of this Warrant will be, exempt from the registration requirements of the Securities Act, and are exempt from the qualification requirements of any applicable state securities laws; and neither Company nor anyone acting on its behalf will take any action hereafter that would cause the loss of such exemptions.

 

18.4 Listing; Stock Issuance. Company shall use commercially reasonable efforts to secure and maintain the listing of the Common Stock or other securities issuable upon exercise of this Warrant, upon each securities exchange or over-the-counter market upon which securities of the same class or series issued by Company are listed, if any. Upon exercise of this Warrant, Company will use commercially reasonable efforts to cause stock certificates representing the shares of Common Stock purchased pursuant to the exercise to be issued in book-entry form in the names of Holder, its nominees or assignees, as appropriate at the time of such exercise.

 

18.5 Charter Documents. Company has provided Holder with true and complete copies of Company’s Charter, By-Laws, and each Certificate of Designation or other charter document setting, forth any rights, preferences and privileges of Company’s capital stock, each as amended and in effect on the date of issuance of this Warrant.

 

19. Counterparts; Facsimile. This Warrant may be executed by one or more of the parties hereto in any number of separate counterparts, all of which together shall constitute one and the same instrument. Holder’s execution and delivery of Holder’s counterpart signature page to this Warrant via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall constitute Holder’s effective execution and delivery of this Warrant and agreement to and acceptance of the terms hereof for all purposes.

 

[Remainder of this page intentionally left blank; signature page follows]

 

 
 

 

[Signature Page to Warrant]

 

IN WITNESS WHEREOF, Company has caused this Warrant to be duly executed by its officer, thereunto duly authorized as of the date of issuance set forth on the first page hereof.

 

BEYOND AIR, INC.  
     
By: /s/ Steve Lisi  
Name: Steve Lisi  
Title: Chief Executive Officer  
     
AGREED AND ACCEPTED:  
   
HOLDER:  
   
AVENUE VENTURE OPPORTUNITIES FUND, L.P  
   
By: Avenue Venture Opportunities Partners, LLC  
Its: General Partner  
     
By: /s/ Sonia Gardner  
Name: Sonia Gardner  
Title: Authorized Signatory  

 

 
 

 

FORM OF SUBSCRIPTION

 

(To be signed only upon exercise of Warrant)

 

To:  
   
The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder, (1) ________________ (_____) shares1 (the “Shares”) of Common Stock and herewith makes payment of _____________ Dollars ($________) therefor, and requests that the certificates for such shares be issued in the name of, and delivered to, _________, whose address is ___________.
   
The undersigned hereby elects to net exercise ________________ (_____) shares (the “Shares”) of Common Stock, and requests that the certificates for such shares be issued in the name of, and delivered to, _________, whose address is ___________..

 

The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 17 of this Warrant and by its signature below hereby makes such representations and warranties to Company.

 

  Dated  
     
  Holder:  
     
  By:  
     
  Its:  
     
  (Address)
   
   
   
   

 

 

1 Insert here the number of shares called for on the face of the Warrant (or, in the case of a partial exercise, the portion thereof as to which the Warrant is being exercised), in either case without making any adjustment for additional Warrant Shares or any other stock or other securities or property or cash which, pursuant to the adjustment provisions of the Warrant, may be issuable upon exercise.

 

 
 

 

ASSIGNMENT

 

FOR VALUE RECEIVED, the undersigned, the holder of the within Warrant, hereby sells, assigns and transfers all of the rights of the undersigned under the within Warrant, with respect to the number of shares of Common Stock covered thereby set forth herein below, unto:

 

Name of Assignee   Address   No. of Shares
         
         
         
         
         
         
         
         
         
         

 

  Dated  
     
  Holder:  
     
  By:  
     
  Its:  

 

 
 

 

EXHIBIT “A”

 

[On letterhead of Company]

 

Reference is hereby made to that certain Warrant dated June 21, 2024 issued by BEYOND AIR, INC., a Delaware corporation (the “Company”), to AVENUE VENTURE OPPORTUNITIES FUND, LP, a Delaware limited partnership (the “Holder”).

 

Notice is hereby given pursuant to Section 4.5 of the Warrant that the following adjustment(s) have been made to the Warrant: [describe adjustments, setting forth details regarding method of calculation and facts upon which calculation is based].

 

This certifies that Holder is entitled to purchase from Company __________________________, at the Holder’s option, (____________) fully paid and nonassessable shares of Company’s _________ Stock at an exercise price of _________________________ Dollars ($__________) per share The applicable Exercise Price and the number of shares purchasable under the Warrant remain subject to adjustment as provided in Section 4 of the Warrant.

 

Executed this ___ day of ________________, 20___.

 

  BEYOND AIR, INC.
     
  By:  
     
  Name:  
     
  Title:  

 

 

 

GRAPHIC 3 ex4-1_001.jpg GRAPHIC begin 644 ex4-1_001.jpg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end EX-4.2 4 ex4-2.htm

 

Exhibit 4.2

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

Date of Issuance: June 21, 2024

 

WARRANT TO PURCHASE

 

SHARES OF COMMON STOCK OF

 

BEYOND AIR, INC.

 

(Void after June 30, 2029)

 

This certifies that AVENUE VENTURE OPPORTUNITIES FUND II, L.P, a Delaware limited partnership, or permitted assigns (“Holder”), for value received, is entitled to purchase from BEYOND AIR, INC., a Delaware corporation (“Company”), the Applicable Number (hereinafter defined) of fully paid and nonassessable shares of the Company’s Common Stock (the “Common Stock”), for cash, at a purchase price per share equal to the Exercise Price (hereinafter defined). Holder may also exercise this Warrant on a cashless or “net issuance” basis as described in Section 1(b) below, and this Warrant shall be deemed to have been exercised in full on such basis on the Expiration Date (hereinafter defined), to the extent not fully exercised prior to such date. This Warrant is issued in connection with that certain Loan and Security Agreement and Supplement thereto, both of even date herewith (as amended, restated and supplemented from time to time, the “Loan Agreement” and the “Supplement”, respectively), between Company, as borrower, and Holder, as one of the lenders (“Lender”). Capitalized terms used herein and not otherwise defined in this Warrant shall have the meaning(s) ascribed to them in the Loan Agreement and the Supplement, unless the context would otherwise require.

 

In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated below:

 

Applicable Number” means 60,000.

 

Exercise Price” means $1.28.

 

Warrant Shares” means the shares of Common Stock purchased hereunder.

 

Subject to Section 4.3, this Warrant may be exercised at any time or from time to time up to and including 5:00 p.m. (Pacific time) on June 30, 2029 (the “Expiration Date”), upon surrender to Company at its principal office at 900 Stewart Avenue, Suite 301, Garden City, NY 11530 (or at such other location as Company may advise Holder in writing) of this Warrant properly endorsed with the Form of Subscription attached hereto duly completed and signed and upon payment in cash or by check of the aggregate Exercise Price for the number of shares for which this Warrant is being exercised determined in accordance with the provisions hereof. The Exercise Price and the number of shares purchasable hereunder are subject to further adjustment as provided in Section 4 of this Warrant.

 

 
 

 

This Warrant is subject to the following terms and conditions:

 

1. Exercise; Issuance of Certificates; Payment for Shares.

 

(a) Unless an election is made pursuant to clause (b) of this Section 1, this Warrant shall be exercisable at the option of Holder, at any time or from time to time, on or before the Expiration Date for all or any portion of the Warrant Shares (but not for a fraction of a share) for the Exercise Price multiplied by the number of Warrant Shares to be purchased. Company agrees that the Warrant Shares purchased under this Warrant shall be and are deemed to be issued to Holder as the record owner of such Warrant Shares as of the close of business on the date on which the form of subscription shall have been delivered and payment made for such Warrant Shares. Subject to the provisions of Section 2, certificates for the Warrant Shares so purchased, together with any other securities or property to which Holder is entitled upon such exercise, shall be delivered to Holder by Company at Company’s expense within a reasonable time after the rights represented by this Warrant have been so exercised. Except as provided in clause (b) of this Section 1, in case of a purchase of less than all the Warrant Shares, Company shall cancel this Warrant and execute and deliver a new Warrant or Warrants of like tenor for the balance of the Warrant Shares surrendered upon such purchase to Holder within a reasonable time. Each stock certificate or book-entry statement so delivered shall be in such denominations of Common Stock as may be requested by Holder and shall be registered in the name of such Holder or such other name as shall be designated by such Holder, subject to the limitations contained in Section 2.

 

(b) Holder, in lieu of exercising this Warrant by the cash payment of the Exercise Price pursuant to clause (a) of this Section 1, may elect, at any time on or before the Expiration Date, to surrender this Warrant and receive that number of Warrant Shares computed using the following formula:

 

 

  Where: X = the number of shares of Common Stock to be issued to Holder.
         
    Y = the number of shares of Common Stock that Holder would otherwise have been entitled to purchase hereunder pursuant to Section 1(a) (or such lesser number of shares as Holder may designate in the case of a partial exercise of this Warrant).
         
    A = the closing price on the last trading day prior to the exercise of the Warrant.
         
    B = the Exercise Price then in effect.

 

Election to exercise under this Section 1(b) may be made by delivering a signed form of subscription to Company via electronic mail, to be followed by delivery of this Warrant. Notwithstanding anything to the contrary contained in this Warrant, if as of the close of business on the last business day preceding the Expiration Date this Warrant remains unexercised as to all or a portion of the Warrant Shares, then effective at 9:00 a.m. (Pacific time) on the Expiration Date, Holder shall be deemed, automatically and without need for notice to Company, to have elected to exercise this Warrant in full pursuant to the provisions of this Section 1(b), and upon surrender of this Warrant shall be entitled to receive that number of Warrant Shares computed using the above formula, provided that the application of such formula as of the Expiration Date yields a positive number for “X”.

 

 
 

 

2. Limitation on Transfer.

 

(a) This Warrant and the Warrant Shares shall not be transferable except upon the conditions specified in this Section 2, which conditions are intended to ensure compliance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”). Each holder of this Warrant or the Warrant Shares issuable hereunder will cause any proposed transferee of the Warrant or Warrant Shares to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Section 2. Notwithstanding the foregoing and any other provision of this Section 2 but subject to the last sentence of Section 2(c), Holder may freely transfer all or part of this Warrant or the shares issuable upon exercise of this Warrant (or the securities issuable, directly or indirectly, upon conversion of the shares, if any) at any time to any affiliate of Lender under the Loan Agreement, by giving Company notice of the portion of the Warrant being transferred setting forth the name, address and taxpayer identification number of the transferee and surrendering this Warrant to Company for reissuance to the transferees(s) (and Holder, if applicable).

 

(b) Each certificate representing (i) this Warrant, (ii) the Warrant Shares, and (iii) any other securities issued in respect of the Warrant Shares issued upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall (unless otherwise permitted by the provisions of this Section 2 or unless such securities have been registered under the Securities Act or sold under Rule 144) be stamped or otherwise imprinted with a legend substantially in the following form (in addition to any legend required under applicable state securities laws):

 

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.

 

(c) Holder of this Warrant and each person to whom this Warrant is subsequently transferred represents and warrants to Company and agrees (by acceptance of such transfer) that it will not transfer this Warrant (or securities issuable upon exercise hereof unless a registration statement under the Securities Act was in effect with respect to such securities at the time of issuance thereof) unless (i) there is an effective registration statement under the Securities Act and applicable state securities laws covering any such transaction, (ii) pursuant to Rule 144 under the Securities Act (or any other rule under the Securities Act relating to the disposition of securities), (iii) Company receives an opinion of counsel, reasonably satisfactory to Company, that an exemption from such registration is available or (iv) the Company otherwise satisfies itself that such transaction is exempt from registration. Notwithstanding the foregoing or any other provision of this Section 2, Holder shall not transfer this Warrant (or securities issuable upon exercise hereof, or securities issuable, directly or indirectly, upon conversion of such securities, if any) to any competitor of Company, as determined in good faith by the Board of Directors of Company (the “Board”), without the prior written consent of Company.

 

 
 

 

(d) Reserved.

 

3. Shares to be Fully Paid; Reservation of Shares. Company covenants and agrees that all Warrant Shares will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any stockholder and free of all taxes, liens and charges with respect to the issue thereof. Company further covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, Company will at all times have authorized and reserved, for the purpose of exercise of the this Warrant, a sufficient number of shares of authorized but unissued Common Stock, or other securities and property, when and as required to provide for the exercise of the rights represented by this Warrant. Company will take all such action as may be necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any domestic securities exchange upon which the Common Stock may be listed. Company will not take any action which would result in any adjustment of the Exercise Price (as described in Section 4 hereof) (i) if the total number of Warrant Shares issuable after such action upon exercise of all outstanding warrants, together with all shares of Common Stock then outstanding and all shares of Common Stock then issuable upon exercise of all options and upon the conversion of all convertible securities then outstanding, would exceed the total number of shares of Common Stock then authorized by Company’s Certificate of Incorporation, as amended and restated from time to time (the “Charter”) or (ii) if the par value per share of the Common Stock would exceed the Exercise Price.

 

4. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 4. Upon each adjustment of the Exercise Price, Holder of this Warrant shall thereafter be entitled to purchase, at the Exercise Price resulting from such adjustment, the number of Warrant Shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares purchasable pursuant hereto immediately prior to such adjustment, and dividing the product thereof by the Exercise Price resulting from such adjustment.

 

4.1 Subdivision or Combination of Stock. In case Company shall at any time subdivide its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately reduced, and conversely, in case the outstanding shares of Common Stock of Company shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be proportionately increased.

 

4.2 Dividends. If at any time or from time to time the holders of Common Stock (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,

 

(a) Common Stock, or any shares of stock or other securities whether or not such securities are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,

 

(b) any cash paid or payable including as a cash dividend, or

 

(c) Common Stock or other or additional stock or other securities or property (including cash) by way of spin off, split-up, reclassification, combination of shares or similar corporate rearrangement, (other than shares of Common Stock issued as a stock split, adjustments in respect of which shall be covered by the terms of Section 4.1 above),

 

then and in each such case, Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clauses (b) and (c) above) which such Holder would hold on the date of such exercise had it been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares and/or all other additional stock and other securities and property.

 

 
 

 

4.3 Change of Control. In the event of a Change of Control (as hereinafter defined), this Warrant shall be automatically exchanged for a number of shares of Company’s securities, such number of shares being equal to the maximum number of shares issuable pursuant to the terms hereof (after taking into account all adjustments described herein) had Holder elected to exercise this Warrant immediately prior to the closing of such Change of Control and purchased all such shares pursuant to the cashless exercise provision set forth in Section 1(b). Company acknowledges and agrees that Holder shall not be required to make any payment (cash or otherwise) for such shares as further consideration for their issuance pursuant to the terms of the preceding sentence. “Change of Control” shall mean any sale, license, or other disposition of all or substantially all of the assets of Company, any reorganization, consolidation, merger or other transaction involving Company where the holders of Company’s securities before the transaction beneficially own less than 50% of the outstanding voting securities of the surviving entity after the transaction; provided that an issuance of equity securities for the primary purpose of raising capital shall not be considered a Change of Control under this Warrant. This Warrant shall terminate upon Holder’s receipt of the number of shares of Company’s equity securities described in this Section 4.3.

 

4.4 Reserved.

 

4.5 Notice of Adjustment. Upon any adjustment of the Exercise Price, and/or any increase or decrease in the number of Warrant Shares purchasable upon the exercise of this Warrant, Company shall give written notice thereof to Holder pursuant to Section 12. The notice, which may be substantially in the form of Exhibit “A” attached hereto, shall be signed by Company’s chief financial officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of Warrant Shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based.

 

4.6 Other Notices. If at any time:

 

(a) Company shall declare any cash dividend upon its Common Stock;

 

(b) Company shall declare any dividend upon its Common Stock payable in stock or make any special dividend or other distribution to the holders of its Common Stock;

 

(c) Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or other rights;

 

(d) there shall be any capital reorganization or reclassification of the capital stock of Company, or consolidation or merger of Company with, or sale of all or substantially all of its assets to, another entity;

 

(e) there shall be a voluntary or involuntary dissolution, liquidation or winding-up of Company; or

 

(f) Company shall take or propose to take any other action, notice of which is actually provided to holders of the Common Stock;

 

then, in any one or more of said cases, Company shall give Holder, pursuant to Section 12, (i) at least 10 days’ prior written notice of the date on which the books of Company shall close or a record shall be taken for such dividend, distribution or subscription rights or for determining rights to vote in respect of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action and (ii) in the case of any such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action, at least 10 days’ written notice of the date when the same shall take place. Any notice given in accordance with the foregoing clause (i) shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common Stock shall be entitled thereto. Any notice given in accordance with the foregoing clause (ii) shall also specify the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, sale, dissolution, liquidation or winding-up, or other action as the case may be.

 

 
 

 

4.7 Certain Events. If any change in the outstanding Common Stock of Company or any other event occurs as to which the other provisions of this Section 4 are not strictly applicable or if strictly applicable would not fairly effect the adjustments to this Warrant in accordance with the essential intent and principles of such provisions, then the Board shall make in good faith an adjustment in the number and class of shares issuable under this Warrant, the Exercise Price and/or the application of such provisions, in accordance with such essential intent and principles, so as to protect such purchase rights as aforesaid. The adjustment shall be such as will give Holder of this Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as Holder would have owned had this Warrant been exercised prior to the event and had Holder continued to hold such shares until after the event requiring adjustment.

 

5. Issue Tax. The issuance of certificates for shares of Common Stock upon the exercise of this Warrant shall be made without charge to Holder of this Warrant for any issue tax in respect thereof; provided, however, that Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of any certificate in a name other than that of the then Holder of this Warrant being exercised.

 

6. Closing of Books. Company will at no time close its transfer books against the transfer of this Warrant or of any Warrant Shares issued or issuable upon the exercise of this Warrant in any manner which interferes with the timely exercise of this Warrant.

 

7. No Voting Rights; Limitation of Liability. Nothing contained in this Warrant shall be construed as conferring upon Holder hereof the right to vote or to consent as a stockholder in respect of meetings of stockholders for the election of directors of Company or any other matters or any rights whatsoever as a stockholder of Company. No dividends or interest shall be payable in respect of this Warrant or the interest represented hereby or the shares purchasable hereunder until, and only to the extent that, this Warrant shall have been exercised; provided, however, that if any dividends are due or paid at any time on the underlying securities for which this Warrant is exercisable, then upon exercise, the securities issued to Holder shall be deemed to have accrued dividends and be paid identical dividends from date of this Warrant. No provisions hereof, in the absence of affirmative action by Holder to purchase shares of Common Stock, and no mere enumeration herein of the rights or privileges of Holder hereof, shall give rise to any liability of such Holder for the Exercise Price or as a stockholder of Company, whether such liability is asserted by Company or by its creditors.

 

8. Amendment of Charter. Unless Holder consents thereto in writing, Company shall not amend its Charter prior to the exercise of this Warrant if the Common Stock would be adversely affected by such amendment in a manner that would be more adverse to Holder with respect to the shares of Common Stock issuable upon the exercise of this Warrant than, and substantially dissimilar to, such amendment’s effect on the other holders of Common Stock.

 

9. Registration Rights. Holder shall be entitled, with respect to the shares of Common Stock issued upon exercise hereof, to the registration rights set forth in Section 3(d) of the Supplement.

 

10. Rights and Obligations Survive Exercise of Warrant. The rights and obligations of Company, of Holder of this Warrant and of the holder of Warrant Shares, contained in Sections 6, 8 and 18 shall survive the exercise of this Warrant.

 

11. Modification and Waiver. This Warrant and any provision hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought.

 

12. Notices. Any notice, request or other document required or permitted to be given or delivered to Holder or Company shall be deemed to have been given (i) upon receipt if delivered personally or by courier (ii) upon confirmation of receipt if by facsimile or email or (iii) three business days after deposit in the US mail, with postage prepaid and certified or registered, to each such Holder at its address as shown on the books of Company or to Company at the address indicated therefor in the opening paragraphs of this Warrant (or at such other location as Company may advise Holder in writing).

 

 
 

 

13. Survival of Certain Obligations. All of the obligations of Company relating to the Warrant Shares issuable upon the exercise of this Warrant shall survive the exercise and termination of this Warrant. All of the covenants and agreements of Company shall inure to the benefit of and be binding upon the successors and permitted assigns of Holder. Company will, at the time of the exercise of this Warrant, in whole or in part, upon request of Holder but at Company’s expense, acknowledge in writing its continuing obligation to Holder in respect of any rights to which Holder shall continue to be entitled after such exercise in accordance with this Warrant; provided, that the failure of Holder to make any such request shall not affect the continuing obligation of Company to Holder in respect of such rights.

 

14. Descriptive Headings and Governing Law. The descriptive headings of the several sections and paragraphs of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Delaware.

 

15. Lost Warrants or Stock Certificates. Company agrees that upon receipt of evidence reasonably satisfactory to Company of the loss, theft, destruction, or mutilation of any Warrant or stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, Company at its expense will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate.

 

16. Fractional Shares. No fractional shares shall be issued upon exercise of this Warrant. Company shall, in lieu of issuing any fractional share, pay the holder entitled to such fraction a sum in cash equal to such fraction multiplied by the then effective Exercise Price.

 

17. Representations of Holder. With respect to this Warrant, Holder represents and warrants to Company as follows:

 

17.1 Experience. It is experienced in evaluating and investing in companies engaged in businesses similar to that of Company; it understands that investment in this Warrant involves substantial risks; it has made detailed inquiries concerning Company, its business and services, its officers and its personnel; the officers of Company have made available to Holder any and all written information it has requested; the officers of Company have answered to Holder’s satisfaction all inquiries made by it; in making this investment it has relied upon information made available to it by Company; and it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of investment in Company and it is able to bear the economic risk of that investment.

 

17.2 Investment. It is acquiring this Warrant and any Warrant Shares issuable upon exercise hereof for investment for its own account and not with a view to, or for resale in connection with, any distribution thereof. It understands that this Warrant and the Warrant Shares issuable upon exercise of this Warrant, have not been registered under the Securities Act, nor qualified under applicable state securities laws.

 

17.3 Rule 144. It acknowledges that this Warrant and the Common Stock issuable upon exercise of this Warrant must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. It has been advised or is aware of the provisions of Rule 144 promulgated under the Securities Act.

 

17.4 Access to Data. It has had an opportunity to discuss Company’s business, management and financial affairs with Company’s management and has had the opportunity to inspect Company’s facilities.

 

17.5 Accredited Investor. It is, and at the time the Warrant was offered was, an “accredited investor” within the meaning of Regulation D promulgated under the Securities Act.

 

 
 

 

17.6 General Solicitation. It is not purchasing this Warrant as a result of any advertisement, article, notice or other communication regarding this Warrant published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to its knowledge, any other general solicitation or general advertisement.

 

18. Additional Representations and Covenants of Company. Company hereby represents, warrants and agrees as follows:

 

18.1 Corporate Power. Company has all requisite corporate power and corporate authority to issue this Warrant and to carry out and perform its obligations hereunder.

 

18.2 Authorization. All corporate action on the part of Company, its directors and stockholders necessary for the authorization, execution, delivery and performance by Company of this Warrant has been taken. This Warrant is a valid and binding obligation of Company, enforceable in accordance with its terms.

 

18.3 Offering. Subject in part to the truth and accuracy of Holder’s representations set forth in Section 17 hereof, the offer, issuance and sale of this Warrant is, and the Common Stock issuable upon exercise of this Warrant will be, exempt from the registration requirements of the Securities Act, and are exempt from the qualification requirements of any applicable state securities laws; and neither Company nor anyone acting on its behalf will take any action hereafter that would cause the loss of such exemptions.

 

18.4 Listing; Stock Issuance. Company shall use commercially reasonable efforts to secure and maintain the listing of the Common Stock or other securities issuable upon exercise of this Warrant, upon each securities exchange or over-the-counter market upon which securities of the same class or series issued by Company are listed, if any. Upon exercise of this Warrant, Company will use commercially reasonable efforts to cause stock certificates representing the shares of Common Stock purchased pursuant to the exercise to be issued in book-entry form in the names of Holder, its nominees or assignees, as appropriate at the time of such exercise.

 

18.5 Charter Documents. Company has provided Holder with true and complete copies of Company’s Charter, By-Laws, and each Certificate of Designation or other charter document setting, forth any rights, preferences and privileges of Company’s capital stock, each as amended and in effect on the date of issuance of this Warrant.

 

19. Counterparts; Facsimile. This Warrant may be executed by one or more of the parties hereto in any number of separate counterparts, all of which together shall constitute one and the same instrument. Holder’s execution and delivery of Holder’s counterpart signature page to this Warrant via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) shall constitute Holder’s effective execution and delivery of this Warrant and agreement to and acceptance of the terms hereof for all purposes.

 

[Remainder of this page intentionally left blank; signature page follows]

 

 
 

 

[Signature Page to Warrant]

 

IN WITNESS WHEREOF, Company has caused this Warrant to be duly executed by its officer, thereunto duly authorized as of the date of issuance set forth on the first page hereof.

 

BEYOND AIR, INC.  
     
By: /s/ Steve Lisi  
Name: Steve Lisi  
Title: Chief Executive Officer  

 

AGREED AND ACCEPTED:  
   
HOLDER:  
   
AVENUE VENTURE OPPORTUNITIES FUND II, L.P.  
     
By: Avenue Venture Opportunities Partners II, LLC  
Its: General Partner  

 

   
By: /s/ Sonia Gardner  
Name: Sonia Gardner  
Title: Authorized Signatory  

 

 
 

 

FORM OF SUBSCRIPTION

 

(To be signed only upon exercise of Warrant)

 

To: _____________________________

 

The undersigned, the holder of the within Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder, (1) ________________ (_____) shares1 (the “Shares”) of Common Stock and herewith makes payment of _____________ Dollars ($________) therefor, and requests that the certificates for such shares be issued in the name of, and delivered to, _________, whose address is ___________.
  
The undersigned hereby elects to net exercise ________________ (_____) shares (the “Shares”) of Common Stock, and requests that the certificates for such shares be issued in the name of, and delivered to, _________, whose address is ___________..

 

The undersigned acknowledges that it has reviewed the representations and warranties contained in Section 17 of this Warrant and by its signature below hereby makes such representations and warranties to Company.

 

  Dated  
       
  Holder:    
       
  By:    
       
  Its:    
       
  (Address)    
       
     
     

 

 

1 Insert here the number of shares called for on the face of the Warrant (or, in the case of a partial exercise, the portion thereof as to which the Warrant is being exercised), in either case without making any adjustment for additional Warrant Shares or any other stock or other securities or property or cash which, pursuant to the adjustment provisions of the Warrant, may be issuable upon exercise.

 

 
 

 

ASSIGNMENT

 

FOR VALUE RECEIVED, the undersigned, the holder of the within Warrant, hereby sells, assigns and transfers all of the rights of the undersigned under the within Warrant, with respect to the number of shares of Common Stock covered thereby set forth herein below, unto:

 

Name of Assignee   Address   No. of Shares
         
         
         
         
         

 

  Dated  
     
  Holder:  
     
  By:  
     
  Its:  

 

 
 

 

EXHIBIT “A”

 

[On letterhead of Company]

 

Reference is hereby made to that certain Warrant dated June 21, 2024 issued by BEYOND AIR, INC., a Delaware corporation (the “Company”), to AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership (the “Holder”).

 

Notice is hereby given pursuant to Section 4.5 of the Warrant that the following adjustment(s) have been made to the Warrant: [describe adjustments, setting forth details regarding method of calculation and facts upon which calculation is based].

 

This certifies that Holder is entitled to purchase from Company __________________________, at the Holder’s option, (____________) fully paid and nonassessable shares of Company’s _________ Stock at an exercise price of _________________________ Dollars ($__________) per share The applicable Exercise Price and the number of shares purchasable under the Warrant remain subject to adjustment as provided in Section 4 of the Warrant.

 

Executed this ___ day of ________________, 20___.

 

  BEYOND AIR, INC.
     
  By:  
     
  Name:  
     
  Title:  

 

 

 

GRAPHIC 5 ex4-2_001.jpg begin 644 ex4-2_001.jpg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end EX-10.1 6 ex10-1.htm

 

Exhibit 10.1

 

First Amendment to Loan Documents

 

This First Amendment to Loan Documents (this Amendment) is entered into as of June 21, 2024, by and among AVENUE CAPITAL MANAGEMENT II, L.P., a Delaware limited partnership (as administrative and collateral agent (in such capacity, “Agent)), AVENUE VENTURE OPPORTUNITIES FUND, L.P., a Delaware limited partnership (Avenue), AVENUE VENTURE OPPORTUNITIES FUND II, L.P., a Delaware limited partnership (Avenue 2; and, collectively with Avenue, Lendersand each, individually, a Lender), and BEYOND AIR, INC., a Delaware corporation (“Borrower”) and BEYOND AIR LTD., an Israeli private company, company # 514609387 (Israeli Guarantor” or “Beyond Israel).

 

RECITALS

 

Borrower, Agent and Lenders are parties to those certain Loan Documents, dated as of June 15, 2023, including the Loan and Security Agreement (as amended from time to time, the Agreement) and the Supplement to Loan and Security Agreement (as amended from time to time, the Supplement). The parties desire to amend the Agreement and the Supplement in accordance with the terms of this Amendment.

 

NOW, THEREFORE, the parties agree as follows:

 

1. The following terms and their definitions in Part 1 of the Supplement hereby are amended and restated in their entireties to read as follows:

 

“Final Payment” means a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) equal to (x) three and one-half of one percent (3.50%) of the original Commitment amount of Twenty Seven Million Five Hundred Thousand Dollars ($27,500,000), plus (y) solely in connection with repayment of the Growth Capital Loans on the Maturity Date or a prepayment of the Growth Capital Loans in full, Eighty-Seven Thousand Five Hundred Dollars ($87,500).

 

“Interest-only Period” means the period commencing on the Closing Date and continuing until June 30, 2025; provided, however, that such period may be extended until June 30, 2026 if, as of the last day of the Interest-only Period then in effect (a) Borrower has fully drawn Tranche 2 and (b) Borrower has achieved at least Forty Million Dollars ($40,000,000) in Product Revenue for the fiscal year ending March 31, 2025 and has provided reasonably satisfactory evidence of the same to Agent; provided, further, however, that the Interest-only Period shall not exceed thirty-six (36) months.

 

2. Part 2, Section 2(a) of the Supplement hereby is amended and restated in its entirety to read as follows:

 

(a) Warrant. As additional consideration for the making of its Commitment, each Lender has earned and is entitled to receive immediately upon the execution of the Loan and Security Agreement and this Supplement, a warrant instrument issued by Borrower (as modified, amended or amended and restated from time to time, and whether issued as of the Closing Date or otherwise, the “Warrant”).”

 

3. No course of dealing on the part of Lender, nor any failure or delay in the exercise of any right by Lender, shall operate as a waiver thereof, and any single or partial exercise of any such right shall not preclude any later exercise of any such right. Lender’s failure at any time to require strict performance by Borrower of any provision shall not affect any right of Lender thereafter to demand strict compliance and performance. Any suspension or waiver of a right must be in writing signed by an officer of Lender.

 

4. Unless otherwise defined, all initially capitalized terms in this Amendment shall be as defined in the Loan Documents (as defined in the Agreement). The Loan Documents, as amended hereby, shall be and remain in full force and effect in accordance with their respective terms and hereby are ratified and confirmed in all respects. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment of, any right, power, or remedy of Lender under the Loan Documents, as in effect prior to the date hereof.

 

 
 

 

5. Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Documents, as amended by this Amendment. The organizational documents of Borrower delivered to Agent on the Closing Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect. The authorized signatories identified to the Agent as of the Closing Date as authorized on behalf of Borrower to execute and deliver the Loan Documents remain so authorized and the signatory to this Amendment is authorized and directed to execute and deliver this Amendment.

 

6. As a condition to the effectiveness of this Amendment, Agent and/or the applicable Lender shall have received, in form and substance reasonably satisfactory to Agent and the Lenders, the following:

 

(a) this Amendment, duly executed by Borrower;

 

(b) [intentionally omitted];

 

(c) a Warrant to Purchase Shares of Stock of Borrower, duly executed by Borrower and issued to each Lender;

 

(d) an amendment fee, in the amount of $87,500, which shall be due and payable in full (and may be debited or ACH’d by Agent) on the date of this Amendment;

 

(e) all reasonable out-of-pocket attorneys’ fees, costs and expenses incurred in connection with the preparation and negotiation of this Amendment, which Borrower shall remit via wire transfer on the date of execution of this Amendment per the instructions set forth on Annex I hereto; and

 

(f) such other documents, and completion of such other matters, as Agent or any Lender may have reasonably requested.

 

7. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one instrument. This Amendment may be executed by electronic signatures.

 

[Remainder of page intentionally left blank]

 

 
 

 

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first above written.

 

  BORROWER:
     
  BEYOND AIR, INC.
     
  By: /s/ Steve Lisi
  Name: Steve Lisi
  Title: Chief Executive Officer

 

GUARANTOR:
     
  BEYOND AIR LTD.
   
  By: /s/ Steve Lisi
  Name: Steve Lisi
  Title: Chief Executive Officer

 

Address for Notices: 900 Stewart Avenue, Suite 301 
  Garden City, New York 11530
  Attn: Steve Lisi, Chief Executive Officer
  Email: slisi@beyondair.net

 

[Signature Page to First Amendment to Loan Documents]

 

 
 

 

AGENT:

 

  AVENUE CAPITAL MANAGEMENT II, L.P.
     
  By: Avenue Venture Opportunities Partners, LLC
  Its: General Partner
     
  By: /s/ Sonia Gardner
  Name: Sonia Gardner
  Title: Authorized Signatory

 

Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director
  Email:                                                         
  Phone #                 

 

LENDERS:

 

  AVENUE VENTURE OPPORTUNITIES FUND, L.P.
     
  By: Avenue Venture Opportunities Partners, LLC
  Its: General Partner
     
  By: /s/ Sonia Gardner
  Name: Sonia Gardner
  Title: Authorized Signatory

 

Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director
  Email:                                                                   
  Phone #                      

 

  AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
     
  By: Avenue Venture Opportunities Partners II, LLC
  Its: General Partner
     
  By: /s/ Sonia Gardner
  Name: Sonia Gardner
  Title: Authorized Signatory

 

Address for Notices: 11 West 42nd Street, 9th Floor
  New York, New York 10036
  Attn: Todd Greenbarg, Senior Managing Director
  Email:                                        
  Phone #                  

 

[Signature Page to First Amendment to Loan Documents]

 

 
 

 

Annex I
Barnes & Thornburg Wire Instructions

 

Lender’s legal fees and expenses: $                

 

  Account Name:                                                                                                                            
     
  Bank Name:

                                         

     
  Account Number:                                          
     
  ABA Number:                                          
     
  ABA Number:                                          
     
  SWIFT Code:                                          
     
  Reference:                                          
     
  Please send remittance information to:                                                                                                                               

 

 

 

EX-99.1 7 ex99-1.htm

 

Exhibit 99.1

 

Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

 

Appointed industry veteran, David Webster, as new Chief Commercial Officer

 

Recently upgraded LungFit PH device expands customer base; revenue growth expected to accelerate each quarter going forward

 

FY 2025 revenue guidance revised to greater than $10 million

 

Implemented capital conservation strategy to reduce cash burn

 

Conference call scheduled for 4:30 p.m. ET today, June 24th

 

GARDEN CITY, N.Y., June 24, 2024 Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced its financial results for the fiscal fourth quarter and year ended March 31, 2024, and provided a corporate update.

 

“I am proud of the Beyond Air team’s accomplishments throughout our fiscal year (FY) 2024, which positions the Company for growth over the coming year and beyond,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “Throughout the past year, we successfully navigated challenges during the initial soft launch of LungFit PH and emerged with a stronger solution and commercial infrastructure. These improvements have positively impacted our sales pipeline and existing customer engagements, which are expected to be reflected in our topline performance over the coming quarters. Two upcoming milestones that are expected to drive additional revenue growth include the pending FDA decision on the cardiac surgery indication and development of a second generation LungFit PH system.”

 

“Over the past few months, we implemented a strategy to conserve capital as we continue building momentum around the commercial launch of LungFit PH. This will significantly reduce our quarterly spend going forward. The impacted R&D projects include our VCAP program, which was placed on hold, and our LungFit GO home-based device for NTM and other lung infections, which we are now bringing in-house for design and development, resulting in a modest delay. We continue to target initiation of the next clinical study for the NTM program during calendar year 2026. Separately, our cancer and autism programs are anticipated to be self-funded. Given these adjustments, we expect our operations to be funded through at least July 2025,” stated Mr. Lisi.

 

 
 

 

Recent Highlights and Upcoming Milestones

 

LungFit® PH

 

Commercial demand continues to increase for LungFit PH, as evidenced by:
To date, LungFit PH devices have been used in more than 50 hospitals
To date, over 1,100 patients have been treated with LungFit PH, accounting for more than 75,000 hours of treatment
Current customers extend across 10 states in the U.S.
Appointed David Webster as new Chief Commercial Officer to lead commercial operations
FDA decision expected in the fourth quarter of CY 2024 for the pending PMA supplement for cardiac surgery
Awaiting updates on timing for CE Mark for LungFit PH in Europe
Updated revenue guidance to greater than $10 million for FY 2025, from the previous guidance of $12 million to $16 million

 

Beyond Cancer - Solid Tumor Program

 

Ultra high concentration Nitric Oxide (UNO) therapy is in an ongoing Phase 1a trial evaluating advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors
The ongoing Phase 1a trial reported encouraging first-in-class clinical data demonstrating evidence of immune system activation via biomarker response in a heavily pretreated population. These data were presented at the American Society of Clinical Oncology Key Opinion Leader Event held in conjunction with the 2024 Annual Meeting
Upon regulatory approval, a Phase 1b trial will enroll up to 20 subjects with prior exposure to anti-PD-1 antibody that have either progressed, not achieved a response, or have prolonged stable disease (≥ 12 weeks) on single agent anti-PD-1 without radiographic evidence of continued tumor reduction. Subjects enrolled in the Phase 1b trial will be treated with UNO + anti-PD-1 combination upon completion of the Phase 1a trial prior to the end of this year

 

Capital Conservation Strategy

 

The Company implemented a capital conservation strategy that will extend its cash runway and focus its resources on ramping up the commercial program for LungFit PH and maintain the timeline for the second generation LungFit PH
Reduced headcount by over 20% since January 1, 2024
Study of LungFit® PRO to treat viral community-acquired pneumonia (VCAP) has been placed on hold due to strategic prioritization
The trials evaluating LungFit® GO for the treatment of nontuberculous mycobacteria (NTM) and COPD have been placed on hold due to strategic prioritization; and the design and development of the LungFit GO device will be performed in-house and LungFit GO will be ready for clinical studies in calendar year 2026
Beyond Cancer subsidiary – planned Phase 1b clinical trial of UNO in combination with anti-PD1 will begin enrollment by the end of calendar 2024
NeuroNOS subsidiary – plan to initiate first-in-human autism spectrum disorder (ASD) study in 2025, pending available funding
Net cash burn rate is expected to be less than $30 million in FY 2025, which assumes the Company hits certain revenue targets. The quarter ended June 30, 2024 will include initial costs associated with implementing the capital preservation strategy. Net cash burn is expected to continue to decline in FY 2026 with an expectation that the Company will achieve cash flow breakeven in the fourth fiscal quarter of 2026.

 

 
 

 

Financial Results for the Fiscal Year Ended March 31, 2024

 

Revenues for the fiscal year ended March 31, 2024 were $1.2 million compared to zero for the fiscal year ended March 31, 2023. Cost of revenue of $2.5 million was recognized for the fiscal year ended March 31, 2024, compared to $0.6 million for the three months ended March 31, 2023.

 

Research and development expenses for the fiscal year ended March 31, 2024 were $24.4 million compared to $16.8 million for the fiscal year ended March 31, 2023. The increase of $7.6 million was due primarily to an increase in development costs associated with the pipeline.

 

General and administrative expenses for the fiscal years ended March 31, 2024 and March 31, 2023 were $37.3 million and $34.7 million, respectively. The $2.6 million increase was mainly due to increases in stock-based compensation, headcount and salary inflation.

 

Net loss attributed to common stockholders for the fiscal year ended March 31, 2024, was ($60.2) million or a loss of ($1.82) per share, basic and diluted. The Company’s net loss attributed to common stockholders for the fiscal year ended March 31, 2023 was ($55.8) million or a loss of ($1.86) per share, basic and diluted.

 

Adjusted cash burn in the fiscal year ended March 31, 2024 was $46.2 million, which excludes $6.6 million non-recurring items for payments of non-product related litigation and $2.5 million of additional funds requested by our third-party manufacturer to secure long lead-time materials.

 

Over the course of the fiscal year, the Company received net proceeds of $13.4 million from its ATM, $15.8 million in net debt, and $14.6 million from the sale of securities through a securities purchase agreement to partially offset the Company’s cash burn.

 

As of March 31, 2024, the Company reported cash, cash equivalents, and marketable securities of $34.5 million.

 

Conference Call & Webcast

 

Monday, June 24th @ 4:30 PM ET

Domestic:1-877-407-0784
International:1-201-689-8560
Conference ID:13746892
Webcast:A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call.

 

 
 

 

About Beyond Air®, Inc.

 

Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

 

About Nitric Oxide

 

Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.

 

About LungFit®*

 

Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

 

* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.

 

 
 

 

About PPHN

 

Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.

 

About Viral Community-Acquired Pneumonia (VCAP)

 

In adults, viruses have been identified as the causative agents in approximately 100 million cases of community-acquired pneumonia per year. While viral pneumonia in adults is most commonly caused by rhinovirus, respiratory syncytial virus (RSV) and influenza virus, newly emerging viruses (including SARS-CoV-1, SARS-CoV-2, avian influenza A, and H1N1 viruses) have been identified as pathogens contributing to the overall burden of adult viral pneumonia. Patients aged 65 years or older are at particular risk for death from the disease, as are patients with other underlying health conditions or weakened immune systems. There is no consensus regarding the use of antiviral drugs to treat viral pneumonia, and specific preventative measures are currently limited to the influenza vaccine. Given that current treatment recommendations are largely limited to supportive care, there is an unmet medical need for effective treatment options. NO may prove to be a treatment as the impact on the lung should result in bronchodilation, reduction in inflammation and inhibition of the viral replication process.

 

About NTM

 

NTM infection is a rare and serious bacterial infection in the lungs causing debilitating pulmonary disease associated with high morbidity and mortality. NTM infection is acquired by inhaling aerosolized bacteria from the environment, and can lead to NTM lung disease, a progressive and chronic condition. According to the Cystic Fibrosis Foundation, 13% of U.S. cystic fibrosis patients had a positive culture for a NTM species in 2017. NTM is considered an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines suggest a combination of multiple antibiotics dosed chronically for as long as two years. These complex, expensive and invasive regimens have a poor record in the treatment of Mycobacterium abscessus complex (MABSC) and refractory Mycobacterium avium complex (MAC) and have the potential to cause severe adverse events. Beyond Air’s system is designed to deliver 150 – 400 ppm NO to the lungs, and early data, including from the pilot study of the LungFit GO, indicate that this range of NO concentrations could have a positive effect on patients infected with NTM.

 

 
 

 

About Beyond Cancer, Ltd.

 

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in patients with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols.

 

For more information, visit www.beyondcancer.com.

 

About UNO Therapy for Solid Tumors

 

Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. UNO therapy is a completely new approach to preventing relapse or metastatic disease. In vitro murine data show that local tumor ablation with UNO stimulates an anti-tumor immune response in solid tumor cancer models. The Company believes that UNO has the potential to prevent relapse or metastatic disease with as little as a single 5-minute treatment and with limited toxicity or off-target effects.

 

About ASD

 

ASD is a serious neurodevelopmental and behavioral disorder, and one of the most disabling conditions and chronic illnesses in children. ASDs include a wide range of developmental disorders that share a core of neurobehavioral deficits manifested by abnormalities in social interactions, deficits in communication, restricted interests, and repetitive behaviors. In 2023, the CDC reported that approximately 1 in 36 children in the U.S. is diagnosed with an ASD. On average, ASD costs an estimated $60,000 a year through childhood, with the bulk of the costs in special services and lost wages related to increased demands on one or both parents. Mothers of children with ASD, who tend to serve as the child’s case manager and advocate, are less likely to work outside the home. On average, they work fewer hours per week and earn 56 percent less than mothers of children with no health limitations and 35 percent less than mothers of children with other disabilities or disorders. The cost of caring for Americans with autism reached $268 billion in 2015 and is expected to rise to $461 billion by 2025 in the absence of more-effective interventions and support across the life span.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

 

CONTACTS:

 

Investor Relations contacts

Corey Davis, Ph.D.

LifeSci Advisors, LLC

Cdavis@lifesciadvisors.com

(212) 915-2577

 

++++++

 

 
 

 

BEYOND AIR, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except share and per share data)

 

   March 31, 2024   March 31, 2023 
         
ASSETS          
Current assets          
Cash and cash equivalents  $11,378   $29,158 
Marketable securities   23,090    16,724 
Restricted cash   230    7,610 
Accounts receivable   319    - 
Grant receivable   -    420 
Inventory   2,127    1,129 
Other current assets and prepaid expenses   6,792    4,369 
           
Total current assets   43,936    59,410 
Licensed right to use technology   1,427    1,632 
Right-of-use lease assets   2,121    2,493 
Property and equipment, net   9,364    5,003 
Other assets   113    212 
TOTAL ASSETS  $56,961   $68,749 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable  $1,948   $2,016 
Accrued expenses and other current liabilities   8,402    16,613 
Operating lease liability, current portion   418    376 
Loans payable, current portion   800    775 
Total current liabilities   11,567    19,780 
           
Operating lease liability, net   1,898    2,321 
Long-term debt, net   14,721    120 
Warrant liability   275    - 
Derivative liability   1,314    - 
Other long-term liabilities   -    4,500 
Total liabilities   29,775    26,721 
           
Stockholders’ equity          
Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding   -    - 
Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 45,900,821 and 30,738,585 shares issued and outstanding as of March 31, 2024 and 2023, respectively   5    3 
Treasury stock   (25)   (25)
Additional paid-in capital   264,780    217,339 
Accumulated deficit   (239,697)   (179,455)
Accumulated other comprehensive income /(loss)   (15)   53 
Total stockholders’ equity attributable to Beyond Air, Inc.   25,048    37,915 
Non-Controlling Interest   2,138    4,113 
Total equity   27,186    42,028 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $56,961   $68,749 

 

 
 

 

BEYOND AIR, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(amounts in thousands, except share and per share data)

 

  

Year Ended

March 31, 2024

  

Year Ended

March 31, 2023

 
         
Revenue  $1,159   $- 
           
Cost of revenue   (2,466)   (555)
           
Gross loss   (1,307)   (555)
           
Operating expenses          
Research and development   (24,363)   (16,810)
General and administrative   (37,337)   (34,694)
Total operating expenses   (61,700)   (51,504)
           
Loss from operations  $(63,006)  $(52,059)
           
Other income (expense)          
           
Dividend and interest income   1,739    656 
Change in fair value of warrant liability   611    - 
Change in fair value of derivative liability   48    - 
Estimated contingent loss   (598)   (7,863)
Other expense   (169)   - 
Interest and finance expense   (2,912)   (30)
Foreign exchange loss   (6)   (105)
Total other income /(expense)   (1,288)   (7,342)
           
Net loss before income taxes   (64,295)   (59,401)
           
Provision for income taxes   -    - 
           
Net loss  $(64,295)  $(59,401)
           
Less: net loss attributable to non-controlling interest   (4,053)   (3,585)
           
Net loss attributable to Beyond Air, Inc.  $(60,242)  $(55,816)
           
Other comprehensive loss, net of tax:          
Foreign currency translation gain (loss)   (68)   (43)
           
Comprehensive loss attributable to Beyond Air, Inc.  $(60,310)  $(55,859)
           
Net basic and diluted loss per share attributable to Beyond Air, Inc.  $(1.82)  $(1.86)
           
Weighted average number of shares of common stock outstanding – basic and diluted   33,160,180    29,973,639 

 

 

 

EX-101.SCH 8 xair-20240621.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 9 xair-20240621_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 10 xair-20240621_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 21, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 21, 2024
Entity File Number 001-38892
Entity Registrant Name Beyond Air, Inc.
Entity Central Index Key 0001641631
Entity Tax Identification Number 47-3812456
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 900 Stewart Avenue
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Garden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (516)
Local Phone Number 665-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $.0001 per share
Trading Symbol XAIR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 17 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://beyondair.net/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm xair-20240621.xsd xair-20240621_lab.xml xair-20240621_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "XAIR", "nsuri": "http://beyondair.net/20240621", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "xair-20240621.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "xair-20240621_lab.xml" ] }, "presentationLink": { "local": [ "xair-20240621_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 23 }, "report": { "R1": { "role": "http://beyondair.net/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://beyondair.net/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 20 0001493152-24-025433-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-025433-xbrl.zip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end XML 22 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001641631 2024-06-21 2024-06-21 iso4217:USD shares iso4217:USD shares false 0001641631 8-K 2024-06-21 Beyond Air, Inc. DE 001-38892 47-3812456 900 Stewart Avenue Suite 301 Garden City NY 11530 (516) 665-8200 false false false false Common Stock, par value $.0001 per share XAIR NASDAQ false